Biomarker ID | 235 |
PMID | 17460773 |
Year | 2007 |
Biomarker | ARL6IP+MYH11 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:- Smooth muscle contraction,Sema4D in semaphorin signaling,Muscle cont,Semaphorin interactions,Viral myocarditisraction |
Experiment | Primary Vs Metastatic Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | Two prostate cancer data sets including the Pittsburgh and the LaTulippe et al. (Memorial Sloan- Kettering Cancer Center, MSKCC) data sets were retrieved to distinguish metastatic prostate cancer (MET) and PCA |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | NA |
Method Used | NA |
Clinical | No |
Remarks | Results on Stanford Data Set (Validation Set). Classifier Used: IF (ARL6IP > MYH11) THEN MET |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Dataset |
Technical Name | ARL6IP1, MYH11 |